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Transplanting cell cultured brown adipocytes (BAs) represents a promising approach to prevent and treat obesity
(OB) and its associated metabolic disorders, including type 2 diabetes mellitus (T2DM). However, transplanted
BAs have a very low survival rate in vivo. The enzymatic dissociation during the harvest of fully differentiated
BAs also loses significant cells. There is a critical need for novel methods that can avoid cell death during cell
preparation, transplantation, and in vivo. Here, we reported that preparing BAs as injectable microtissues could
overcome the problem. We found that 3D culture promoted BA differentiation and UCP-1 expression, and the
optimal initial cell aggregate size was 100 μm. The microtissues could be produced at large scales via 3D sus
pension assisted with a PEG hydrogel and could be cryopreserved. Fabricated microtissues could survive in vivo
for long term. They alleviated body weight and fat gain and improved glucose tolerance and insulin sensitivity in
high-fat diet (HFD)-induced OB and T2DM mice. Transplanted microtissues impacted multiple organs, secreted
protein factors, and influenced the secretion of endogenous adipokines. To our best knowledge, this is the first
report on fabricating human BA microtissues and showing their safety and efficacy in T2DM mice. The proposal
of transplanting fabricated BA microtissues, the microtissue fabrication method, and the demonstration of effi
cacy in T2DM mice are all new. Our results show that engineered 3D human BA microtissues have considerable
advantages in product scalability, storage, purity, safety, dosage, survival, and efficacy.

1. Introduction
According to World Health Organization data, about 10% of adults
have obesity (OB), and the population with OB-associated type 2 dia
betes mellitus (T2DM) will reach 300 million by 2025 [1]. Currently, no
safe and long-lasting approaches exist to prevent/treat OB and T2DM
[2]. Healthy humans have a substantial amount of brown adipose tissue
(BAT), a tissue that can augment the whole-body energy expenditure
[3–8]. Large clinical data shows BAT activity inversely correlates to

body mass index, plasma glucose, and triglycerides levels, insulin
resistance. BAT activity is a negative predictor of T2DM, dyslipidemia,
coronary artery disease, cerebrovascular disease, congestive heart fail
ure, and hypertension [3–8]. Furthermore, the beneficial effects of BAT
are more pronounced in obese individuals, suggesting the importance of
this tissue for the obese population [3–8]. Clinical studies have shown
that augmenting BAT activities using pharmaceuticals (e.g., mirabegron
[9], glucocorticoids [10], BIBO3304 [11]), or cold stimulation [12–15]
enhances the whole-body energy expenditure, glucose tolerance, and
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insulin sensitivity [16–18]. These findings suggest that BAT is a prom
ising therapeutic target. However, these BAT-activating approaches
require sustained treatments, have significant side effects [19], and may
not work for long term. Additionally, they may work poorly on patients
with a low abundance of BAT, such as obese and aged individuals.
An alternative approach that can overcome these problems is to
augment BAT mass and activity via tissue or cell transplantation. Several
groups transplanted three-dimensional (3D) BAT (0.1–0.2 g) obtained
from healthy mouse donors to diet-induced or genetically obese mice
[20–23]. The transplantation significantly reduced plasma glucose, tri
glyceride, lipid levels, body weight gain, fat composition, and hepatic
steatosis [22,23] while increasing the body energy expenditure, oxygen
consumption rate (OCR), glucose homeostasis, and insulin sensitivity
[24,25]. Transplanted BAT could directly burn fatty acids and glucose
and dissipate the energy as heat via nonshivering thermogenesis (e.g.,
act as an energy sink) [18,19]. They also secreted soluble factors and
exosomes that enhanced glucose uptake and energy expenditure in the
heart, muscle, and white adipose tissue (WAT) (e.g., act as an endocrine
organ) [16,26–30]. These pre-clinical data show that BAT trans
plantation is a promising way to prevent and treat OB and its associated
metabolic disorders. Although few studies have used T2DM mice as
recipients, research found that transplanting mouse BAT into Strepto
zotocin (STZ)-induced diabetic mice prevented and reversed type 1
diabetes mellitus (T1DM) [24,31].
To date, most transplantation studies used mouse BAT since human
BAT is located in deep organs, e.g., the supraclavicular, perirenal/ad
renal, and paravertebral regions, and isolating sufficient human BAT for
transplantation and research is challenging [32,33]. Thus transplanting
human brown adipocytes (BAs) prepared via in vitro cell culture is
necessary. Researchers recently isolated and immortalized human
brown adipocyte progenitors (BAPs) and showed they could be effi
ciently expanded and differentiated into functional BAs in vitro [32,33].
When transplanted along with Matrigel, these BAPs could mature into
functional BAs in vivo and prevent/reverse diet-induced OB and meta
bolic disorders [34]. Additionally, a few research groups successfully
differentiated human pluripotent stem cells (hPSCs) into BAs and
showed they were metabolically active in vitro and in mice models
[35–43]. Thus both primary BAPs and hPSCs can be used as sources to
prepare functional BAs for transplantation.
A critical challenge of transplanting in vitro prepared BAs is their low
survival rate in vivo. A recent study showed that only 2.7% of mature BA
(differentiated from immortalized mouse BAPs in vitro) were live in
SCID mice 7 days after transplantation with Matrigel [21]. Conse
quently, BAs showed no efficacy in vivo [21]. We also found that the
enzymatic dissociation during the harvest of the fully differentiated BAs
cultured in the conventional 2D cell culture dishes killed many cells. To
improve the survival rate during cell preparation, transplantation, and
in vivo, most published studies transplanted BAPs and let these cells
mature into functional BAs in vivo. For instance, the same study found
that 12.1% of immortalized mouse BAPs survived 7 days after trans
plantation with Matrigel [21]. It should be noted that although the
survival rate was improved, a 12.1% rate was still low. However, there
are significant concerns with transplanting BAPs. First, the differentia
tion efficiency in vivo is typically low, and a large percentage of trans
planted BAPs become non-BA cells, raising safety concerns [21]. Second,
a large number of BAPs are typically injected to compensate for the low
differentiation efficiency and survival rate. For instance, the Tseng study
transplanted 1.5-2x107 BAPs per animal [34]. About 1.5-2x1010 BAPs
would be needed for a human, considering the human body volume is
about 1000 times of mouse body volume. This will make the cost of
goods very high. Third, BAPs are still proliferating and have a tissue
overgrowth risk, especially for immortalized cells. Lastly, researchers
typically inject BAPs with Matrigel to restrict the cells at the trans
plantation site and enhance their survival [21]. However, Matrigel is
extracted from mouse tumor tissue. It is not chemically defined and not
compatible with clinical applications.

In short, transplanting BAPs is not an ideal approach. Transplanting
fully differentiated BAs has advantages in that they can be prepared in
vitro at high purity (e.g., ~93% in this study). They are less likely to
have uncontrolled growth in vivo since they already exit the cell cycle.
However, approaches must be developed to improve their survival rate
in vivo and avoid cell death during cell harvest and transplantation in
vitro. We propose that preparing BAs as injectable 3D microtissues can
overcome these problems. Here, we report the BA microtissue fabrica
tion method, their survival, safety, and capability to improve glucose
and insulin homeostasis and manage body weight gain in HFD-induced
OB and T2DM mice. Our results show that engineered 3D human BA
microtissues have considerable advantages in product scalability, stor
age, purity, safety, dosage, survival, and efficacy.
2. Methods
2.1. 2D cell culture and differentiation
Immortalized BAPs are gifts from Dr. Tseng at Harvard University
[32,33]. We followed published methods to culture and differentiate
BAPs [32,33]. Briefly, BAPs were cultured in Dulbecco’s Modified Eagle
Media (DMEM, HyClone, #SH30003.03) supplemented with 10% FBS
(Atlanta biologicals, #S11150). When cells reached 80% confluence,
they were passaged (1:3) with 0.25% trypsin-EDTA (Giboco,
#25200056). To induce differentiation, BAPs were seeded at 0.5 × 104
cells/cm2 and maintained in the growth media to reach confluence.
Then cells were cultured in differentiation media I consisting EBM-2
(Lonza, #CC-3156), 0.1% FBS, 5 μM SB431542 (Selleckchem,
#S1067), 25.5 μg/ml ascorbic acid (Sigma, #A89605G), 4 μg/ml hy
drocortisone (Sigma, #H0396), 10 ng/ml Epidermal Growth Factor
(Peprotech, # 100-15), 0.2 nM 3,3′ ,5-Triiodo-L-thyronine (T3, Sigma,
#T2877), 170 nM insulin (Sigma, #I9287-5 ML), 1 μM rosiglitazone
(Sigma, #R2408), 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX, Sigma,
#I5879) and 0.25 μM dexamethasone (Sigma, #D4902) for 3 days, then
in differentiation media II (differentiation media I without IBMX and
dexamethasone) with media change once a week. Mature BAs could be
obtained 20–30 days after induction.
2.2. Fabricating 3D BA microtissues
Aggrewells (Stemcell Technologies #34815, #34425) were pretreated with an anti-adherence rinsing solution (Stemcell Technolo
gies, #07010) following the manufacturer’s instruction. Single BAPs
were seeded into Aggrewells with differentiation media I. Differentia
tion media II was used after three days and refreshed once a week.
Differentiated BA microtissues were collected by centrifugation at 100g
for 3 min. To prepare 3D BA microtissues in shaking plates, single BAPs
were suspended in differentiation media I in a low adhesion 6-well plate
(Corning, #3471) shaking at 75 rpm. Detailed methods of culturing cells
in shaking plates can be found in our previous publications [44–48].
Differentiation media II was used after three days and refreshed once a
week. The plate was tilted and placed in static for 5 min to settle down
the microtissues to change the media. 90% of the exhausted media was
replaced with fresh media. BA microtissues were collected by pipetting
the media up and down to suspend the microtissues and spinning at 100
g for 3 min.
To prepare 3D BA microtissues in thermoreversible hydrogels, single
BAPs were suspended in growth media I in low adhesion 6-well plate
shaking at 75 rpm overnight to form BAP spheres. The spheres were then
mixed with 10% ice-cold PNIPAAm-PEG (Cosmo Bio, #MBG-PMW205005) solution dissolved in DMEM media. The mixture was then cast on
a tissue culture plate and incubated at 37 ◦ C for 10 min to form a
hydrogel before adding the pre-warmed differentiation media I. Differ
entiation media II was used after three days and refreshed once a week.
To harvest BA microtissues, the media was removed, and ice-cold DPBS
(Life Technologies, #21600044) was added to dissolve the hydrogel for
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5 min. Finally, BA microtissues were collected by spinning at 100 g for 3
min. Detailed methods of encapsulating cells in this thermoreversible
hydrogel can be found in our previous publications [44,48–52].
The prepared BAs were characterized for glucose uptake. WAs were
used as controls. Methods to prepare WAs from WAPs were described in
our previous publication [53]. Briefly, the differentiated BA and WA
were incubated with serum-free DMEM containing 1 g/L D-(+)-glucose
and 20 pM human insulin for 24 h before the glucose uptake test. Cells
were incubated with HBSS buffer for 10 min before adding 4 nM of
[3H]-2-deoxyglucose. The [3H]-associated radioactivity was measured
by a liquid scintillation counter over 90 min.
To characterize the oxygen consumption rate (OCR), day 17 BA
microtissues were treated with 0.25% trypsin-EDTA, dissociated into
single cells plus small cell clusters, and plated to the Seahorse micro
plate. Cells were cultured for 7 more days before testing. The oxygen
concentration in the cells was measured by XF24 extracellular flux
analyzer (Seahorse) as described previously [53]. Briefly, oligomycin (1
μM) was added to measure the ATP turnover. Carbonyl cyanide 4-tri
fluoromethoxy phenylhydrazone (0.3 μM) was added to measure the
maximum respiratory capacity. The mitochondrial respiration was
blocked by 1 μM antimycin A and 1 μM rotenone. The OCR was pre
sented by plotting the oxygen concentration in the medium as a function
of time (pmol O2/min).
For the qPCR measurement, total RNA was extracted using TRIzol
reagent (Life Technologies), and 1 μg of RNA was reverse transcribed by
iScript (Biorad). Gene expression was determined by real-time qPCR
(Quant Studio 6 Flex Real-Time PCR, Applied Biosystems) using SYBR
green (Fisher Scientific), and relative gene expression was determined
based on the 2− ΔΔCT method with normalization of the raw data to 18S.
All primer sequences are available in Supplemental Table S1.

WT HFD.
Blood samples were collected from the mouse tail regularly to
measure glucose concentrations. Cells were removed via centrifugation
at 3000g for 10 min at 4 ◦ C. The supernatant was transferred into a new
tube and centrifuged at 3000 g for 5 min at 4 ◦ C to collect the serum.
Mouse fat and lean mass were analyzed by Minispec LF50 (Bruker, USA).
For the glucose tolerance test (GTT), mice were fasted overnight for 16
h. Glucose (0.75 g/kg body weight) was administrated via intraperito
neal injection. Blood samples were collected to measure the glucose
level at 0 (baseline), 30, 60, 90, and 120 min after injection. For the
insulin tolerance test (ITT), mice were fasted in the morning for 8 h.
Insulin (Sigma, #I9278-5 ML, 0.75 U/kg body weight) was administered
via intraperitoneal injection. Blood samples were collected to measure
the glucose level at 0 (baseline), 30, 60, and 90 min after injection.
2.4. Immunocytochemistry
Cells cultured on 2D were fixed with 4% paraformaldehyde (PFA) at
room temperature for 15 min, permeabilized with 0.25% Triton X-100
for 10 min, and blocked with 5% donkey serum for 1 h before incubating
with primary antibodies (Table S2) in DPBS + 0.25% Triton X-100 + 5%
donkey serum at 4 ◦ C overnight. After washing, secondary antibodies
(Table S2) were added and incubated at room temperature for 2 h, fol
lowed by incubating with 10 mM 4′ ,6-Diamidino-2-Phenylindole,
Dihydrochloride (DAPI) for 10 min. Cells were washed with DPBS three
times before imaging with a Fluorescent Microscopy (Zeiss, Germany).
For 3D microtissues immunostaining, microtissues were fixed with 4%
PFA at 4 ◦ C overnight. 40 μm thick tissue sections were obtained via
cryosection. The sections were washed with DPBS three times and
stained as the 2D cell cultures.
For in vivo studies, mouse tissues were harvested and fixed with 4%
PFA at 4 ◦ C overnight. 5 μm thick sections were obtained via paraffin
embedding and section. The sections were deparaffined with xylene
three times and rehydrated sequentially in 100%, 95%, 70%, 50%
ethanol, and distilled water. For hematoxylin and eosin (H&E) staining,
rehydrated sections were stained in Mayers Hematoxylin (Ricca Chem
ical Company, #3530-16) for 1 min, washed in distill water for 5 times,
in DPBS once, and in distilled water 3 times with 1 min for each wash
and stained in Eosin (Fisher, #SE23-500D) for 1 min. The sections were
then dehydrated in 95% ethanol (3 times), 100% ethanol (2 times), and
xylene (3 times) with 1 min for each wash before being mounted with
coverslips. For immunostaining, heat-induced epitope retrieval was
done on rehydrated tissue sections using the antigen retrieval buffer
(Abcam, #ab93680) following the manufacturer’s instruction. The
sections were stained as the 2D cell cultures.
For flow cytometry, microtissues were dissociated into single cells
with 0.25% trypsin-EDTA. Single cells were fixed with 4% PFA and
stained with primary antibodies at 4 ◦ C overnight. After washing (three
times) with 1% BSA in DPBS, secondary antibodies were added and
incubated at room temperature for 2 h. Finally, cells were washed with
1% BSA in DPBS and analyzed using CytoFLEX LX (Beckman Coulter, U.
S.A.). Isotype controls served for negative gating.
To measure the plasma cytokines using mouse adipokine array and
human obesity array, mice were sacrificed. Blood was collected, and
serum was isolated, as described above. Then, 100 μL serum was applied
to the mouse adipokine array (R&D systems, #ARY-013) following the
manufacturer’s instruction. 70 μL serum was applied to the human
obesity array (RayBiotech, #QAH-ADI-3-2) following the manufac
turer’s instructions.

2.3. 3D microtissues transplantation studies
The animal experiments were conducted following the protocols
approved by the University of Nebraska–Lincoln Animal Care and Use
Committee. 6 mice were used for each study group. 6-week-old male
B6.129S7-Rag1tm1Mom/J or Rag1 knock-out mice (Rag1− /− ) were
purchased from Jackson. Mice were transplanted with 1.25 million cells
suspended in DPBS (Rag1− /− HFD+BAT). Mice transplanted with DPBS
were used as a sham control (Rag1− /− HFD+DPBS). Briefly, 3D micro
tissues were collected and transferred into a sample loading tip bent to
have a U-shape. The tips were connected to a PE50 tube (BD Diagnostics
system, #427516), and microtissues were slowly pushed into the center
of the tube using a pipetman. The PE50 tube with microtissues was then
bent into U-shape and placed into a microcentrifuge tube with both the
PE50 tube ends kinked and facing up. The EP tube was centrifuged at
1000 rpm for 10 s to pack the microtissues tightly so that the media was
located at the two ends. The PE50 tube was connected to a loading tip
again. Microtissues were slowly pushed to one end of the PE50 tube
using a pipetman. This operation removed the media so that no media
was injected into the kidney capsule.
The right kidney of an anesthetized mouse was exposed. A small
scratch on the flank of the kidney was made by a 25-gauge needle,
creating a nick in the kidney capsule. Saline was applied with a cotton
swab to keep the kidney wet. The PE50 tube was inserted into the
capsule to make a small pocket under the capsule. Microtissues were
slowly pushed into the pocket. The PE50 tube was carefully retracted,
and the nick was cauterized with low heat. After stopping the bleeding,
saline was applied, and the kidney was placed back. Details can be found
in previous publications [54,55]. After 18 days of transplantation sur
gery, Rag1− /− mice without BA transplantation were fed with a normal
chow diet or NCD. (Research diets, #D12450Ji) or HFD. (Research diets,
#D12492i) and labeled as Rag1− /− NCD and Rag1− /− HFD, respec
tively. Rag1− /− mice transplanted with BA microtissues were fed with
HFD and labeled Rag1− /− HFD+BAT. Wild-type (WT) mice without BA
transplantation were fed with NCD or HFD and labeled as WT NCD and

2.5. Statistical analysis
The data are presented as the mean ± SEM Unpaired t-test and oneway analysis of variance (ANOVA) were used to compare two and more
than two groups, respectively. Two-way ANOVA was used to compare
mice metabolic curves and arrays. P < 0.05 was considered statistically
520
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Fig. 1. 3D culture enhanced BA differentiation. (A) BA differentiation protocol. (B) 3D BA microtissues in microwells on day 17 and their immunostaining. HuNu:
human nuclear antigen. (C) Flow cytometry analysis of UCP-1 expression on day 17 for BAs prepared in 2D culture and 3D culture with varied aggregate sizes. (D)
The mean fluorescent intensity (MFI) of UCP-1 as measured with flow cytometry in (C). (E) The day 17 BA microtissues were plated on 2D surface for 6 days and
stained for UCP-1 expression. Data are represented as mean ± SEM (n = 3). ****p < 0.0001.
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Fig. 2. BA microtissues survived in vivo. (A) The transplantation protocol. Photos and H&E staining of 1-month and 5-month transplants are shown. Only the right
kidney had transplant. The transplants are outlined. The transplant and adjacent kidney tissue are labeled in H&E stain images. Immunostaining of the 5-month
transplant and adjacent kidney tissue with human UCP1 (hUCP1) (B), mouse CD31 (mCD31) (C), and mouse tyrosine hydroxylase (mTH) (D).

significant.

isolated from the superficial neck fat of a human subject and have been
well characterized and documented [32,33]. We previously optimized a
protocol to efficiently differentiate these BAPs into metabolically active
BAs [53]. Given the intimate relationship between BAs and capillary
networks in vivo, we pre-exposed BAPs to endothelial growth media
(EGM) for 48 h before BA differentiation. The pre-exposure significantly
promoted brown differentiation efficiency and metabolic activities. We

3. Results
3.1. Fabricating 3D BA microtissues
The brown adipocyte progenitors (BAPs) used in this study were
522
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Fig. 3. BA microtissues alleviated obesity and diabetes. (A) Body weight gain, (B) % fat mass, (C) % lean mass, (D) fasting glucose level, (E) GTT (day 150), and (F)
ITT (day 170). WT: wild type mouse; Rag1− /− : Rag1 knock-out mice; NCD: normal chow diet; HFD: high fat diet. BAT: brown adipose microtissues. Data are
represented as mean ± SEM (n = 6). *p < 0.05, ***p < 0.001, ****p < 0.0001.

applied the same differentiation protocol to prepare BA microtissues in
3D. Single BAPs were placed in microwells (Aggrewells). Cells associ
ated with each other, gradually contracted, and formed compact
spheroids after 24 h (Fig. S1A). Like the 2D differentiation, we cultured
the microtissues in differentiation media I for 3 days and then in dif
ferentiation media II with a media refresh every 7 days (Fig. 1A).
Microtissues grew in size significantly during the differentiation
(Fig. S1A). For instance, microtissues with an initial diameter of 100 μm
became 200 μm on day 17 (Fig. S1A). The microtissue size growth can
result from the cell number increase due to cell proliferation or the cell
size increase, or both. Cell proliferation and size growth were observed
during the differentiation of BAPs to BAs in 2D culture [56]. Immuno
staining showed that most of the cells in the microtissues expressed the
UCP-1 protein, a biomarker of mature and functional BAs (Fig. 1B).
UCP-1 is a mitochondria membrane protein critical for nonshivering
thermogenesis [57,58].
To study if the microtissue size influences the differentiation effi
ciency, we prepared microtissues with a diameter of 100, 250, and 450
μm (initial diameter) via seeding different numbers of cells and differ
entiated them. All microtissues grew in size significantly (Fig. S2). While
the 100 and 250 μm microtissues maintained spherical, the 450 μm

microtissues gradually became non-spherical (Fig. S2D). Cell death
(Fig. S2D, red arrows) and fusion between microtissues (Fig. S2D, blue
arrows) were observed only in the 450 μm microtissues. On day 17, flow
cytometry analysis showed 92.6%, 72.6%, and 80.4% of the cells in the
100, 250, and 450 μm microtissues were UCP-1 positive. For compari
son, 2D culture resulted in 78.8% UCP-1 positive cells (Fig. 1C). The
mean fluorescent intensity (MFI) of UCP-1 intensity in 100 μm micro
tissues was significantly higher than in other groups (Fig. 1D).
When the day 17 microtissues were placed in a conventional tissue
culture plate, they adhered to the surface, and individual cells migrated
out (Fig. 1E, S1B, S1C). These cells had the classical BA characteristics.
They expressed a high level of UCP-1 protein (Fig. 1C, 1D, 1E, S3D) and
had multiple small oil droplets (Fig. 1E, S3A, S3B, S3C) and a high
mitochondrial content (Fig. S3C). Furthermore, they expressed the
typical BA marker genes at high levels (Fig. S3E). In addition, the
differentiated BA showed a significantly higher glucose uptake and ox
ygen consumption rate compared to WA (Fig. S4). Our data show that i)
BAP can be differentiated into BA in 3D to prepare BA microtissues; ii) a
3D microenvironment promotes brown adipogenesis and UCP-1
expression. However, a small microtissue size should be used to maxi
mize the benefits.
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Fig. 4. BA microtissue transplants impacted endogenous BAT (endoBAT). (A) H&E staining of endoBAT. Oil droplet size (B) and area (C) in endoBAT. (D) Mouse
UCP-1 and CD31 expression in endoBAT. (E) Mouse TH and CD31 expression in endoBAT. Data are represented as mean ± SEM (n = 6). ****p < 0.0001.
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Fig. 4. (continued).

3.2. BA microtissue transplantation studies

of the transplanted BAT were significantly bigger than those of the
endoBAT of NCD-fed mice (Fig. 4A). A high level of UCP-1 protein was
observed in the transplanted BAT (Fig. 2B). Host blood vessels grew into
the transplants (Fig. 2C). The vessel density was comparable to the
endoBAT of HFD mice but lower than the endoBAT of NCD mice
(Fig. 4D). Innervation is critical for BA function [62]. Tyrosine hy
droxylase (TH+) nerves were found in the transplants (Fig. 2D), and
their density was comparable to the endoBAT of HFD mice but lower
than the endoBAT of NCD mice (Fig. 4E).
We regularly measured the body weight, fat and lean mass, plasma
glucose level, glucose tolerance, and insulin sensitivity (Fig. 3). To
mimic the β cell dysfunction of T2DM, we injected low-dose STZ (90 mg/
kg) after 3-month HFD. The body weight drops, and the fasting glucose
level rise after the STZ injection, indicating the progression of T2DM
(Fig. 3A and D). There was no significant difference in total diet intake
between the HFD groups. Under HFD, both WT and Rag1− /− mice
developed OB (Fig. 3A) and grew large fat masses (Fig. 3B and C). We
found Rag1− /− mice were slightly more prone to HFD-induced OB and
metabolic disorders but were suitable for our studies. The transplant
significantly reduced the body weight gain, fat content, and fasting
glucose level while increasing insulin sensitivity and glucose tolerance

Next, we studied if the 3D BA microtissue could be transplanted via
injection and if they could survive and function in vivo. As said, very few
BAT transplantation studies used T2DM mice. To fill the gap, we used a
high-fat diet (HFD)-induced OB and T2DM mouse model to test the
fabricated BA microtissues. We selected the immune-deficient Rag1− /−
mice as recipients since they tolerate xenogeneic and allogeneic tissues
and have HFD-induced OB and metabolic disorders [59,60]. In addition,
they developed diabetes when given STZ [61]. Rag1− /− mice fed with a
normal chow diet (NCD) and HFD with DPBS transplantation were used
as positive and negative controls to evaluate the microtissue efficacy.
WT mice fed with NCD and HFD were also included to assess the dif
ference in response to HFD between WT and Rag1− /− mice. HFD was
initiated 18 days post-transplantation. A significant number of adipose
tissue was found in the kidney capsule 1 month and 5 months after
transplantation (Fig. 2A). H&E staining showed the dense kidney tissue
and the adjacent adipose tissue with large amounts of oil droplets
(Fig. 2A). The oil droplets were bigger in the 5-month sample. No tumor
or non-adipose tissues were found in the transplants, indicating the
safety of fully differentiated BAs in vivo. We found that the oil droplets
525
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Fig. 5. BA microtissues reduced endogenous WAT hypertrophy and liver steatosis. (A) H&E staining of mouse subcutaneous white adipose tissue (scWAT). Adipose
size (B) and area (C) in scWAT. (D) Mouse CD31 expression in scWAT. (E) H&E staining of mouse liver. (F) Adipose area in liver. Data are represented as mean ±
SEM (n = 6). *p < 0.05, **p < 0.01, ****p < 0.0001.
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Fig. 5. (continued).

(Fig. 3). In summary, fabricated 3D BA microtissues were successfully
injected into the kidney capsule, survived well, and maintained UCP-1
protein expression for at least 5 months. The transplants were effec
tive in alleviating HFD-induced OB and metabolic syndrome.

mice (Fig. 5D). The liver fat content was significantly increased in
HFD mice but was almost normalized by BA microtissues (Fig. 5E). The
areas occupied by oil droplets in NCD, HFD, and HFD plus BA trans
plantation mice were 18.24%, 42.52%, and 23.76%, respectively. The
results showed that the transplanted microtissues profoundly affected
multiple organs.
We used a Human Obesity Antibody Array to measure human protein
factors in the blood. We found that the concentrations of human adi
ponectin, chemerin, and TGF-β1 in mice with transplants were signifi
cantly higher than background (Fig. 6A), indicating the transplanted
BAs were secreting soluble factors. Research has shown that adiponectin
secreted by white and brown adipocytes has a protective role in obesityassociated metabolic and cardiovascular diseases. Adiponectin in
fluences multiple tissues, such as the liver, skeletal muscle, and vascular
system. Adiponectin can increase insulin sensitivity [63,64], suppress
inflammation, and reduce atherosclerosis [65–67]. Plasma adiponectin
level negatively correlates with obesity, and adiponectin deficiency
enhances HFD-induced insulin resistance [68]. Chemerin plays a posi
tive role in metabolic health [69,70]. TGF-β1 is a mediator of insulin
resistance in metabolic disease [71,72]. We also used a Mouse Adipo
kine Antibody Array to measure 38 obesity-related mouse molecules.
The levels of adiponectin, ANGPT-L3, C-reactive protein, ICAM-1,
IGFBP-3, IGFBP-5, IGFBP-6, lipocalin-2, and pentraxion2 were signifi
cantly reduced, and the IGF-1 concentration was increased by the HFD.
(Fig. 6B and C). The transplanted BA microtissues normalized all of these
molecules (Fig. 6C). Thus, the transplanted microtissues significantly
affected the expression levels of endogenous adipokines.

3.3. BA microtissue transplants impacted multiple organs in vivo
We characterized the impact of the BA transplant on the morphology
and structures of different mouse organs. For the endogenous BAT
(endoBAT), HFD increased the size of oil droplets (Fig. 4A–C). The BA
transplants prevented the increase. For instance, the areas occupied by
oil droplets in NCD, HFD, and HFD plus BA transplantation mice were
43.8%, 71.9%, and 48.9%, respectively. The mean diameter of oil
droplets were 8.6 μm, 12.4 μm, and 9.0 μm in NCD, HFD, and HFD plus
BA transplantation mice, respectively. Compared to NCD mice, HFD
mice had reduced mUCP-1 protein expression (Fig. 4D), blood vessel
density (Fig. 4D and E), and TH+ nerve density (Fig. 4E). The trans
planted BA microtissues significantly improved the mUCP-1 protein
expression, blood vessel density, and TH+ nerve density in HFD mice. In
general, HFD mice with BA microtissues had similar BA morphology,
blood vessel, and nerve densities to the NCD mice.
The adipocyte size and oil droplets of subcutaneous WAT (scWAT)
were increased by the HFD. BA microtissues significantly reduced these
increases (Fig. 5A–C). The areas occupied by oil droplets in NCD, HFD,
and HFD plus BA transplantation mice were 68.7%, 90.5%, and 77.1%,
respectively. The mean diameter of adipocytes were 42.0 μm, 96.2 μm,
and 70.6 μm in NCD, HFD, and HFD plus BA transplantation mice,
respectively. CD31 staining showed fewer blood vessels in HFD-fed
mice. BA microtissues increased the blood vessel density in HFD-fed
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Fig. 6. BA microtissues secreted human protein factors and modulated endogenous adipokines. (A) Protein factors in mouse plasma detected using human obesity
antibody array. (B, C) Heatmap and quantification of adipokines in mouse plasma detected using mouse adipokine antibody array. Data are represented as mean ±
SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

3.4. Scale up BA microtissue production

occurred after long-term culture (e.g., after day 4), resulting in aggre
gates with widely distributed size (Fig. 7A). The final volumetric cell
yield was also low (e.g., ≤1 × 106 cells/mL). It is known that the mass
transport in agglomerates >400 μm in diameter (the diffusion limit in
human tissue) becomes insufficient, leading to cell growth arrest,
apoptosis, and uncontrolled differentiation [74,77]. Thus, suspension
culture alone has difficult to produce the BA microtissues at large scales.
A way to overcome the excessive cellular aggregation is to culture
cells in a hydrogel scaffold. Hydrogels can act as physical barriers to
eliminate excessive cell agglomeration and shear stress [78–81]. We
previously found that single human pluripotent stem cells (hPSCs) could

Although microwells can produce microtissues with precisely
controlled size, microwells are unsuitable for producing microtissues at
large scales for future extensive animal studies, drug screens, and clin
ical applications. 3D suspension culturing, which suspends and cultures
cells in an agitated media, has been extensively studied to scale up cell
production due to its simplicity, easiness of scaling up, and automation
[44,73–76]. We thus investigated if BA microtissues could be prepared
in 3D suspension culture. We found single BAPs associated to form small
uniform aggregates after 24 h. However, severe cell aggregation
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Fig. 7. Scaling up BA microtissue production. Preparing BA microtissues in shaking plates (A) and PEG hydrogel (B). (C)Immunostaining of day 17 BA microtissues
prepared in PEG hydrogel. Microtissues were plated on 2D surface for 6 days before staining.

grow in a thermoreversible PNIPAAm-PEG hydrogel to generate large
amounts of uniform hPSC spheroids [44,49,52,82–86]. We tried
encapsulating single BAPs in the same hydrogel to grow BA micro
tissues. However, single BAPs did not expand in the hydrogel scaffold.
We thus suspended single BAPs in 3D suspension culture for 24 h to
generate small and uniform cell BAP aggregates as described in the
above paragraph. These BAP aggregates were then encapsulated in the
PNIPAAm-PEG hydrogel and cultured for 16 days with differentiation
media to prepare BA microtissues. With this approach, we prepared
large numbers of BA microtissues with well-controlled sizes (Fig. 7B).
The final volumetric yield could reach 1 × 107 cells/mL hydrogel. In
addition, the resultant BAs expressed a high level of UCP-1 protein
(Fig. 7C). Thus, the combination of 1-day suspension culture and 16-day
differentiation in PNIPAAm-PEG hydrogel can be used to scale up the
microtissues production. Lastly, we evaluated if BA microtissues could
be preserved. Microtissues preserved in cell culture media at room
temperature for 24 h (Fig. 8B) had similar viability to the fresh sample
(Fig. 8A). Microtissues could also be cryopreserved in liquid nitrogen for

long-term without significantly sacrificing cell viability (Fig. 8C).
4. Discussion
Our study showed that human BAPs could be differentiated into
mature BAs in 3D to prepare injectable BA microtissues (Fig. 1, S1, S2,
S3). The 3D culture promoted BA differentiation and UCP-1 protein
expression. The optimal initial BAP spheroid size is 100 μm. BA micro
tissues could survive in vivo for long-term (Fig. 2). They significantly
reduced body weight and fat gain and improved glucose tolerance and
insulin sensitivity in HFD-induced OB and T2DM mice (Fig. 3). The
transplanted BA microtissues impacted multiple tissues such as endog
enous BAT, WAT, and liver (Figs. 4 and 5). In addition, they secreted
protein factors and influenced the secretion of endogenous adipokines
(Fig. 6). These microtissues could be produced in large numbers using
3D suspension culture assisted with a thermoreversible PEG hydrogel
(Fig. 7) and could be cryopreserved (Fig. 8). To our best knowledge, this
is the first report on fabricating human BA microtissues and showing
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Fig. 8. Preserving BA microtissues. Live/dead cell staining of day 27 fresh BA microtissues (A), or stored at room temperature for 24 h (B), or stored in liquid
nitrogen and recovered (C).
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their safety and efficacy in OB and T2DM mice. The proposal of trans
planting fabricated BA microtissues, the scalable microtissue fabrication
method, the findings that 3D culture promotes BA differentiation and
the microtissue size affects the differentiation, and the demonstration
that BA transplantation is effective in T2DM mice are all new.
We found that the microtissue size significantly influenced the BA
differentiation efficiency. The optimal diameter is about 100 μm (initial
diameter). BAs have a high demand for glucose, oxygen, and nutrients to
meet their high metabolic activities [21,87–91]. Nutrients are trans
ported in these microtissues mainly through diffusion. Therefore, cells at
the center of large microtissues may not have a sufficient supply of
nutrients, negatively affecting the differentiation process. A second
possible cause is that cells secrete autocrine or/and paracrine factors
that are important to BA differentiation. The microtissue diameter in
fluences the concentrations and gradients of these factors. The exact
reason should be made clear in future studies.
We demonstrated that the production of BA microtissues could be
scaled up using the 3D suspension culture to generate small BAP ag
gregates and followed by differentiating these aggregates in a 3D ther
moreversible hydrogel matrix (Fig. 7). We recently developed a novel
microbioreactor termed AlgTubes, in which cells are cultured in alginate
hydrogel microtubes [45,46,92–97]. AlgTubes are scalable and have low
costs. In addition, the cell aggregate size can be precisely controlled by
the hydrogel tubes. AlgTubes can produce up to 5 × 108 cells per mL of
culture volume. Future studies can apply AlgTubes to produce fibrous
BA microtissues with uniform and precise size at high density.
BAT is among the most vascularized tissues in the body, averaging
~1.2 capillaries per BA (versus only ~0.4 capillaries per white adipo
cyte) [87–91]. A substantial blood supply is required to provide glucose,
fatty acids, nutrients, and oxygen to fuel thermogenesis and rapidly
distribute heat throughout the body [98]. Vascular cells also produce
soluble and insoluble factors critical for BA functions and homeostasis;
conversely, BAs produce a range of growth factors and cytokines that
collectively modulate vascular growth, survival, remodeling, regression,
and blood perfusion [89,91,99]. In obese mice, the capillary density in
BAT decreases significantly (i.e., ~0.5 capillaries per BA), resulting in
hypoxia and BAT degeneration [90]. We found that the transplanted
microtissues gradually became white adipocyte-like in morphology
(Fig. 2A), although UCP-1 proteins were still expressed at a high level
(Fig. 2B). A potential reason for this whitening is the insufficient
vascularization in the transplant. This agrees well with literature find
ings that the transplants had fewer blood vessels than endogenous BAT
[21,100]. Consequently, BAs gradually decreased UCP-1 expression and
became WAT-like features. There are two potential ways to address this
problem. First, as shown in a published study [21], supplementing
vascular endothelial growth factor (VEGF) to the transplant can signif
icantly improve its engraftment, angiogenesis, and function. Second,
endothelial cells can be included in the BA microtissues. As stated in the
above paragraph, endothelial cells or vasculature are indispensable for
BAT in vivo.
We used immortalized BAPs to prepare mature BA microtissues. No
tumor or abnormal tissue growth was observed (Fig. 2), indicating that
fully differentiated BAs are safe in vivo. Thus, it is applicable to isolate
and immortalize BAPs from a patient and expand them to prepare BA
microtissues for personalized BA augmentation therapy. An alternative
approach is to prepare induced pluripotent stem cells (hiPSCs) for a
patient. hiPSCs can be generated by reprogramming somatic cells
[101–103]. They have unlimited proliferation capability and can be
differentiated into all types of somatic cells. The transplant’s immune
rejection can also be avoided by preparing BAT from personalized
hiPSCs [104,105]. Recent clinical studies showed that autologous
hiPSCs-derived dopaminergic neurons and retinal cells were safe and
effective in treating Parkinson’s [106] and macular degeneration [105],
respectively, indicating the coming of the hiPSCs-based personalized
medicine era. Alternatively, universal hiPSCs can be engineered, for
instance, via inactivating major histocompatibility complex (MHC) class

I and II genes and overexpressing CD47 or/and PD-L1 [106–109]. The
derivatives of universal hiPSCs are hypoimmunogenic and can be pre
pared at large scales as “off-the-shelf” allogeneic products. hiPSCs have
been successfully differentiated into BAs that are metabolically active in
vitro and in mice models [35–43]. Therefore, future studies can explore
using hiPSCs to prepare BA microtissues.
Most published studies used obese [20–23] or T1DM mice [24,31]
for BA transplantation. If BA transplantation can prevent/treat T2DM is
still not well-known but is worthy of finding out, considering the size
able T2DM patient population. We preliminarily showed that the
transplanted BA microtissues alleviated HFD-induced body weight and
fat tissue gain and improved glucose homeostasis and insulin sensitivity
in HFD-fed T2DM mice (Fig. 3), showing the high potential of BA
transplantation for preventing/treating T2DM. Previous transplantation
studies found BAT transplants could work through two major mecha
nisms. They could directly burn fatty acids and glucose and dissipate the
energy as heat [18,19] or secreted soluble factors to enhance glucose
uptake and energy expenditure in the heart, muscle, and white adipose
tissue or WAT [16,26–30]. We found that transplanted BA microtissues
impacted the morphology and structure of the mouse organs (Figs. 4 and
5). They also secreted human cytokines and changed the expression
levels of mouse cytokines in plasma (Fig. 6). These indicate that the
second mechanism was active in the transplanted BA microtissues.
Whether the transplants could function through the thermogenesis
mechanism is unknown and should be investigated in the future.
5. Conclusion
Our study showed that 3D BA microtissues could be fabricated at
large scales, cryopreserved for long term, and delivered via injection.
BAs in the microtissues had higher purity and higher UCP-1 protein
expression than BAs prepared via 2D culture. In addition, 3D BA
microtissues had good in vivo survival and no uncontrolled tissue
overgrowth. Furthermore, they showed good efficacy in preventing OB
and T2DM with a very low dosage compared to literature studies. Our
results show that fabricated 3D BA microtissues are promising anti-OB/
T2DM therapeutics. They have considerable advantages over single BAs
or BAPs in terms of product scalability, storage, purity, safety, dosage,
survival, and efficacy.
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